

---

# PHILIPADIB SALEM, M.D.

---

---

---

---

## BIOGRAPHY & BIBLIOGRAPHY

---

Philip Adib Salem, M.D. is a world renowned cancer physician, researcher, educator, author and international medical statesman. He served on the faculty of the M.D. Anderson Cancer Center in Houston, Texas as a professor of cancer medicine from 1987 to 1991. In 1991, Dr. Salem was appointed Director of Cancer Research St. Luke's Episcopal Hospital in Houston, Texas, now known as the Baylor St. Luke's Medical Center, CHI St. Luke's Health, where he is currently Director Emeritus of Cancer Research. Also in 1991, Dr. Salem established the Salem Oncology Center, a private cancer facility in the Texas Medical Center in Houston, Texas, where he continues to serve as President. In 2010, St. Luke's Episcopal Hospital established the Philip A. Salem Chair in Cancer Research to honor Dr. Salem's contributions to cancer medicine. Dr. Salem has published extensively on Immunoproliferative Small Intestinal Disease and the causative relationship of infection to cancer. His research was also crucial in the development of new anticancer agents.



In addition to being a cancer physician and researcher, Dr. Salem is a renaissance intellectual and author. He has extensively published on Lebanese and Middle Eastern Affairs, and he has also written articles ranging from religion to philosophy to human rights. He advanced the concept that the most sacred human right is the right to health. There are nine books that have been written about him and his vision.

## Family life and education

Philip Adib Salem was born in Bterram, El-Koura, North Lebanon on July 13, 1941 to Adib Salem and Lamia Malik. He has five brothers and one sister. Dr. Salem and his wife were married in 1973 and have two daughters and a son.

Dr. Salem completed his elementary and secondary education in El Koura, Lebanon. At the age of 16, he matriculated to the American University of Beirut where, in 1961, he earned a Bachelor of Science degree. In 1965, He graduated with a Doctor of Medicine degree from the School of Medicine of the American University of Beirut, in Beirut, Lebanon. After graduating from medical school, Dr. Salem completed 3 years of residency in Internal Medicine at the American University of Beirut Medical Center.

In 1968, Dr. Salem began a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center in New York, New York. After two years in New York, he moved to Houston, Texas for an additional year of training at the M.D. Anderson Cancer Center.

## Dr. Salem as an academician

In 1971, Dr. Salem returned to Lebanon and joined the full time faculty of the American University of Beirut Medical Center as Assistant Professor and founding Director of the Cancer Research and Treatment Program. In 1978, he was promoted to Associate Professor of Medicine.

In 1987, he returned to the United States and joined the faculty of the M.D. Anderson Cancer Center in Houston, Texas as an Associate Professor of Medicine in the Department of Medical Oncology. In 1990, he was promoted to Professor of Medicine.

In 1991, Dr. Salem was appointed Director of Cancer Research at St. Luke's Episcopal Hospital in Houston, Texas. Also in the same year, he was appointed Adjunct Professor of Medicine at M.D. Anderson Cancer Center, a position he held until 2000. During his tenure in academic medicine, Dr. Salem served on numerous institutional governance committees.

In 2010, St. Luke's Episcopal Hospital, now known as the Baylor St. Luke's Medical Center, CHI St. Luke's Health, established the Philip A. Salem Chair in Cancer Research "as a lasting tribute to his leadership and vision in the field of oncology." Dr. Salem continues to hold this chair today. In 2012, and after 20 years of being Director of Cancer Research, Dr. Salem was named Director Emeritus.

## Dr. Salem as a Physician

During his career, Dr. Salem has treated thousands of cancer patients around the world. Above all else, Dr. Salem considers himself a physician. He embraces the philosophy that, in the practice of medicine, doctors treat people not diseases. Dr. Salem leads the struggle to humanize cancer treatment in America and the world. He believes that knowledge alone is not enough. In addition, patients need love, care, hope, compassion, accessibility to the doctor, and time to talk about their fears, anxieties, and concerns.

Dr. Salem also champions a movement to prohibit government and insurance providers from interfering in the decision making process in the diagnosis and treatment of cancer. He strongly believes that the doctor should have the liberty to treat patients as he thinks is best and be able to practice without fear of litigation for failure to comply with arbitrary standards and guidelines that may not be appropriate for every patient.

## Dr. Salem as a Researcher

Dr. Salem's research focused on three major areas: Immunoproliferative Small Intestinal Disease (IPSID), lymphomas other than IPSID, and new agents and new treatments in cancer.

In the early 1970s, while at the American University of Beirut Medical Center, Dr. Salem described IPSID as a disease of the small intestine. He demonstrated that a chronic repetitive infectious insult to the gastrointestinal mucosa may eventually lead to inflammatory changes, which, if left untreated, may progress to malignancy.

Dr. Salem and his team also elucidated the process through which histopathologically benign lesions progress to malignancy and described the benign phase of IPSID. He demonstrated that the process of inflammation resulting from a chronic repetitive infectious insult is potentially reversible before it becomes malignant. Dr. Salem and his team showed that if IPSID patients are treated with antibiotics while still in the benign phase, the pathology in the small intestine can be reversed to normal, preventing the transition to cancer. This research was one of the first demonstrations of chemoprevention – the reversal of the neoplastic process prior to progression to malignancy.

In 2005, the Nobel Prize in Medicine and Physiology went to 2 Australian researchers, Drs. Barry J. Marshall and J. Robin Warren, who demonstrated the link between infection with *H. pylori* and peptic ulcer and stomach cancer. In the citation, the Nobel Prize Committee recognized the contributions of prior work in this area, including the IPSID research of Dr. Salem, as a gateway for the research that captured the Nobel Prize.

Dr. Salem and his team have also done extensive research on lymphomas in the Middle East. He has delineated the distinctive features of lymphomas in the Middle East and elucidated how lymphomas in the Middle East differ from those seen in the West. He demonstrated that many lymphomas in the Middle East are extra-nodal, with the intestinal forms being the most common. His team also showed that follicular lymphoma is rare in the Middle East and that the most common lymphoma in children there is Burkitt's lymphoma.

Dr. Salem also developed a new method for the delivery of the cancer drug Cisplatin that substantially reduced its toxicity to the kidney. Instead of giving the whole dose of the drug in one injection, Dr. Salem and his team fractionated the dose over five days. This fractionation was useful in helping patients tolerate the drug and in protecting the kidney from irreversible damage. This work served as the basis for the Cisplatin dosing protocols that are currently used around the world, and for the fractionation of the dose of another cancer drug, Adriamycin.

Additionally, Dr. Salem has explored the efficacy of administering anti-cancer agents directly to the liver through intra-arterial hepatic infusion. This work demonstrated success in treating liver cancer including primary and metastatic liver cancer.

Dr. Salem has also been an active participant in clinical trials on chemoprevention of cancer. He was the Principal Investigator at St. Luke's Hospital for a national study investigating the use of Tamoxifen and Raloxifene in preventing breast cancer in high risk women. He also participated in studies investigating the use of Cis-retinoic Acid, a synthetic form of vitamin A, in the prevention of lung, and head and neck cancers. He continues to conduct research in this area.

## Dr. Salem as an Educator

In addition to his roles as a physician and researcher, Dr. Salem has also been an educator. While at the American University of Beirut Medical Center in the 1970's, Dr. Salem established the first fellowship training program in cancer treatment and research in the Middle East.

Throughout his career, Dr. Salem trained hundreds of medical students, residents and fellows. He also coordinated and chaired multidisciplinary tumor conferences at the various hospitals at which he worked, and he participated in hundreds of conferences around the world on cancer research and treatment. He considers public and professional education is key to the conquest of cancer.

## Dr. Salem as an Author and subject of books

The following books have been published:

1. *"Philip Salem – The Man, The Homeland, The Science"* (Arabic). Boutros Indari, Author. Dar Al-Nidal, Beirut, 2004.
2. *"Cancer, Love and the Politics of Hope – the life and vision of Philip A. Salem M.D."* (English). Frances Mourani and Boutros Indari, Authors. Quartet Books Ltd, London, 2012.
3. *"Philip Salem the Rebel, the Scientist and the Humanist"* (Arabic). Maha Samara, Author. Dar Al Saqi and Dar Annahar, Beirut, 2013.
4. *"Philip Salem: Healing the body, Healing the Soul"* (Arabic). Antoine Noujaim, Author. Arts, Sciences and Technology University, Lebanon, 2014.
5. *"Philip Salem: by their Pens"* (Arabic and English). Assaad Khoury, Editor. Maoushy and Zakaria Publisher, Beirut, 2014.
6. *"From the Conquest of Cancer to the Resurrection of Lebanon"* (Arabic) Dr. Philip A. Salem, Author. Notre Dame University, Lebanon.

The following books are still in press:

1. *"Philip Salem and the Message of Lebanon"* (Arabic). Dr. Philip A. Salem, Author. Dar Annahar, Beirut.
2. *"Philip Salem and the Separation of Religion from State"* (Arabic). Jean Dayeh, Author. Dar Annahar, Beirut.
3. *"Philip Salem and Faith"* (Arabic). Telelumiere Television, Lebanon.

## Dr. Salem as an International Medical Statesman

Dr. Salem served on a White House Advisory Committee on Health Care between 1989-1994. He has official agreement with Mexico to train the Mexican cancer doctors in cancer research and treatment on a regular basis. He

has established many collaborative programs in Italy, particularly in Milan, Rome, Napoli, and Palermo. In appreciation for his contributions to Mexico and Italy, he has received many awards and medals from their governments, and cancer institutions. He is also a consultant to many countries in Latin America, Europe and the Middle East on the development of cancer programs.

During his tenure at the American University of Beirut, Dr. Salem has also served as President of the Lebanese Cancer Society, Chairman of the Lebanese National Unit for Cancer Research, and Secretary General of the Federation of Middle East Cancer Organizations. In the 1980s, he served as an ADHOC Chairman of the International Faculty of the UICC Post Graduate Course on Chemotherapy. In the 1990s, he was President of the Arab American Cancer Foundation. Dr. Salem is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Society of Medical Oncology (ESMO), the Texas Medical Oncology Society (TMOS), He has served on the editorial boards and as a reviewer for numerous cancer research journals in the United States, Latin America, Europe, and the Middle East.

## The Salem Oncology Center

Dr. Salem established The Salem Oncology Center in 1991 and continues to serve as its President today.

The Salem Oncology Center is a private cancer facility located in the Texas Medical Center, at 6624 Fannin Street, Houston, Texas. The Center is committed to excellence in the treatment of cancer patients, and to the philosophy of embracing patients with love and compassion.

## The Philip Salem Foundation

After 45 years of practicing cancer medicine, Dr. Salem founded the Philip Salem Foundation.

Dr. Salem believes that the only way to conquer cancer is through research. The Philip Salem Foundation was born out of his passion for research, patient care and educating physicians, patients and the public about cancer.

His Vision for the Philip Salem Foundation includes:

- *Research.* Support and promote cancer research that will contribute to the development of targeted therapy drugs, gene therapy, and cancer prevention.
- *Training.* Support training of doctors, nurses and paramedical professionals engaged in the treatment of cancer, including extended training programs for practicing physicians.
- *Education.* Support education of professionals and the public in the diagnosis and treatment of cancer, through the publication of books, leaflets, articles and other materials, and through the conduct of seminars and lectures.

The Philip Salem Foundation is a 501(c) 3 non-profit organization in the State of Texas.

## Honors and Awards

- [Medal of Achievement, in recognition of research on Mediterranean lymphoma \(IPSID\), Italian Association of Pathologists, 1981](#)

- Citation,for contributions to the success of the journal, by Mary M. Bissey, assistant editor of the journal *Cancer*, 1986
- Who's Who in Lebanon, 1985-present
- Who's Who in the Arab World, 1985-present
- Member, Ad hoc White House Advisory Committee on Health Care, appointed by committee chair Dr. Burton Lee, 1989-1994
- Honoree, for contributions to cancer research, Annual Convention of St. Jude Children's Research Hospital, 1993
- Republican Senatorial Medal of Freedom, 1994
- Goodwill Ambassador for the City of Houston, 1994
- Honoree, for contributions to cancer medicine, American University of Beirut, 1994
- Medal of the Cedars, Lebanon, 1994
- "Man of the Year in Medicine," "ALMAJALLA," International Arab Weekly News Magazine, Arab Press House, London, England, 1994
- National Directory of Who's Who, 1995
- International Who's Who of Professionals, 1995
- "Outstanding cancer physician of the year," Middle East Broadcasting Television Station, London, 1995
- Life Member, National Registry, Who's Who, 1997
- Honoree, for contributions to cancer medicine and for service to Lebanon and mankind, British-Lebanese Association, London, 1997
- Ellis Island Medal of Honor by the National Ethnic Coalition Organizations (NECO), for "exceptional humanitarian efforts and outstanding contributions to American science,"1998
- Member, Ellis Island Medal of Honor Society, 1998
- Commendatore of the Order to the Merit of the Italian Republic (OMRI), 1998
- Distinguished 20<sup>th</sup> Century Republican Leader, Republican Members of the United States Senate, 1998
- Honoree, for contributions to medicine, Arabic literature, philosophy and politics, Cultural Movement of Antelias, Lebanon, 1999
- Khalil Gibran International Award, Arabic Heritage League, Sydney, Australia, 2000

- Arab American of the Year Award, Arab Community Center for Economic and Social Services (ACCESS), Dearborn, Michigan, 2000
- America's Top Doctors, Castle Connolly Guide, Castle Connolly Medical Ltd., 2001-2007
- Who's Who in Executives & Businesses, Nationwide Register's Who's Who, 2001
- "Intellectual of the Year," DiwanAhIAI-Qalam, Beirut, Lebanon, 2002
- Decorated with highest civilian honor by the President of Lebanon, 2002
- Arab American Cultural and Heritage Award, Arab American Cultural and Heritage Center, Houston, Texas 2002
- "Man of the Month," Arrajol Magazine, Saudi Publishing and Distributing Company, London, England. Issue no. 125, pages 18-31, 2003
- Lifetime Achievement Award, Arab Center Congress, 2003
- Featured in the cover story entitled "Dr. Philip Salem, Pivotal Contributor to Cancer Research," Arab American Affairs magazine, Volume 32, Number 212, Pages 40-43, 2004
- Lifetime Achievement Award, American Lebanese National Movement, 2005
- Honoree, 12<sup>th</sup> International Meeting of the Lebanese World Cultural Union, Beirut, Lebanon, 2005
- American Lebanese Medical Association Scientific Achievement Award, American Lebanese Medical Association, 2006
- "The Scientist of the Year," La Fondazione FoedusCultura Impresa Solidarietà, Italy, 2006
- "Intellectual of the Year," MBC television station, Dubai, UAE, 2008
- Honoree, for contributions to medicine and to Lebanon, World Lebanese Cultural Union, 2009
- Marquis Who's Who in America, 2010
- Philip A. Salem Chair in Cancer Research established in honor of Dr. Salem, St. Luke's Episcopal Hospital, Houston, Texas, 2010
- Honorary Doctorate in Humane Letters for contributions to medicine, Arabic literature and philosophy, Lebanese American University, Lebanon, 2010
- Lifetime Achievement Award, Arab American Community and Cultural Centre, Houston, Texas, 2010
- Member of the Board, Arab Thought Forum, 2010

- Featured in the book “*Featured Faculty Members of the American University of Beirut*” as one of the best 15 faculty members in the history of the university. Michel Jeha, Author, Nelson House for Publishing and the American University of Beirut Alumni, 2010
- Distinguished Lifetime Achievement Award, Rene Moawad Foundation, 2012
- Honored, for contributions to cancer medicine and the cause of Lebanon, and as the heir of Dr. DeBakey’s legacy: Excellence in Medicine, Beirut International Award Festival, 2012
- Honoree, for 20 years of service as Director of Cancer Research, St. Luke’s Episcopal Hospital, Houston, Texas 2012
- Honoree, as a physician, intellectual and Lebanese nationalist, Lebanese Circle of Intellectuals (Montada al Shira’ al Fikri), Beirut, 2012
- Honoree, for contributions to medicine, literature and politics, Lions Economic Forum committee, Beirut, 2013
- Honoree, Lebanese Welfare Association for the Handicapped, 2013
- Honorary Doctorate in Humane Letters for contributions to medicine, Arabic literature and philosophy, Notre Dame University of Lebanon, 2013
- The Philip A. Salem Award in Nursing Excellence established in honor of Dr. Salem, Notre Dame University of Lebanon, 2013
- Honoree, University of Arts, Science and Technology, Beirut, 2014
- Honoree, as a distinguished cancer physician and established author and intellectual. The Cultural Council and the Municipality of Byblos, Lebanon, 2014
- Supreme Medal of Excellence, FOEDUS, The Italian Foundation of Culture and Science, 2015

## BIBLIOGRAPHY

PHILIP A. SALEM, M.D.

### Publications

1. Sykes MP, Salem P, Joffe B. Topical 5-fluorouracil: variability of effective dosage and duration of reaction. *J Am GeriatrSoc* 1971;12:977-982.



2. Salem PA. Pulmonary changes and bleomycin. *Cancer Bull* 1971(Jul-Aug);23(4):68-69.
3. Hart JS, Ho DH, George SL, Salem P, Gottleib JA, Frei E 3<sup>rd</sup>. Cytokinetic and molecular pharmacology studies of arabinosylcytosine in metastatic melanoma. *Cancer Res* 1972;32:2711-2716.
4. Luna MA, Bedrossian CW, Lichtiger B, Salem PA. Interstitial pneumonitis associated with bleomycin therapy. *Am J ClinPathol* 1972(Nov);58(5):501-510.
5. Salem P. The rational approach to the cancer patient. (Editorial) *J Med Liban* 1972;25:7-9.
6. Salem PA, Omura G, Clarkson B. Clinicopathological correlations in acute leukemia. Chapter in the proceedings of the Arab Middle East Medical Conference, Syria 1974:pp 221-243.
7. Salem PA. The multi disciplinary approach to cancer. *J Med Liban* 1975;28(1):5-8.
8. Salem PA. Advances in cancer chemotherapy. *J Med Liban* 1975;28(1):9-24.
9. Hajj A and Salem P. Staging in Hodgkin's disease. Techniques and impact on therapy. *J Med Liban* 1975;28:79-87.
10. Salem PA, Nassar V, Hajj A, Balikian G, Alami S, Shamaa M, Salem A. [Clinical Statement. What is called "Mediterranean Lymphoma" at the Hospital Center of the American University in Beirut]. *J Med Liban* 1975;28(2):215-224.
11. Kaufman R, Salem P, Wittes RE. Responsiveness to endocrine manipulation in breast cancer after "prophylactic" castration. *J SurgOncol* 1977;9:39-43.
12. Salem PA, Bodey GP, Burgess MA, Murphy WK, Freireich EJ. A phase I study of pyrazofurin. *Cancer* 1977(Dec); 40(6):2806-2809.
13. Salem PA, Nassar VH, Shahid MJ, Hajj AA, Alami SY, Balikian JB, Salem AA. "Mediterranean abdominal lymphoma," or immunoproliferative small intestinal disease. Part I: clinical aspects. *Cancer* 1977(Dec);40(6): 2941-2947.
14. Salem PA. Oncology overview. Monograph. Selected abstracts on Platinum coordination complexes as anticancer agents. US Department of Health, Education, and Welfare, Service of the International Cancer Research Data Bank (ICRDB) 1977(Oct).
15. Yap HY, Salem P, Hortobagyi GN, Bodey GP Sr, Buzdar AU, Tashima CK, Blumenschein GR. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. *Cancer Treat Rep* 1978;62:405-408.
16. Salem P, Hall SW, Benjamin RS, Murphy WK, Wharton JT, Bodey GP. Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous Iv infusion. *Cancer Treat Rep* 1978;62:1553-1555.
17. Nassar VH, Salem PA, Shahid MJ, Alami SY, Balikian JB, Salem AA, Nasrallah SM. "Mediterranean abdominal lymphoma" or immunoproliferative small intestinal disease. Part II: pathological aspects. *Cancer* 1978(Apr); 41(4):1340-1354.
18. Loo TL, Hall S, Salem PA, Benjamin R, Lu K. Clinical pharmacological and toxicological studies of cis-diamminedichloro-platinum (II) by continuous intravenous infusion. *Biochemie* 1978;60:957-960.
19. Nassar NT, Zurayk HC, Salem PA. Smoking patterns among university students in Lebanon. *J Am Coll Health Assoc* 1980(Apr);28(5):283-285.
20. Issa PY, Salem PA, Brihi E, Azoury RS. Eosinophilic granuloma with involvement of the female genitalia. *Am J ObstetGynecol* 1980(Jul 1);137(5):608-612.
21. Salem PA, Jabboury KW, Khalil MF. Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy. *Oncol* 1982;39(1):31-32.
22. Salem PA, Tabry I, Parsi M, Brihi E. Histiocytic lymphoma presenting with portal hypertension and bleeding esophageal varices: a case report. *J SurgOncol* 1982(May);20(1):37-40.

23. Abdel Karim FW, Ayash RE, Allam C, Salem PA. Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report. *Oncology* 1983;40(3):174-176.
24. Mooradian AD, Allam CK, Khalil MF, Salti I, Salem PA. Anaplastic transformation of thyroid cancer: report of two cases and review of the literature. *J SurgOncol* 1983(Jun);23(2):95-98.
25. Penta JS, Muggia FM, Salem PA. Cisplatin in cancer therapy – Optimization of treatment regimens and toxicity protection. Chapter 6 in *Cancer Chemotherapy I*. Muggia FM, Editor. MartinusNijhoff, The Hague 1983;pp 149-169.
26. Salem P, Khalyl M, Jabboury K, Hashimi L. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. *Cancer* 1984;53:837-840.
27. Salem PA. Systemic therapy of bladder cancer. *ProgClinBiol Res* 1984;162B:95-105.
28. Hashimi LA, Khalyl MF, Salem PA. Supraventricular tachycardia. A probable complication of platinum treatment. *Oncology* 1984;41(3):174-175.
29. Salem PA, Hashimi L, Anaissie E, Khalyl M, Allam C. Primary intestinal lymphoma of adults in the Middle East. *J Chemioterapia* 1985;43:1352.
30. Anaissie E, Geha S, Allam C, Jabbour J, Khalyl M, Salem P. Burkitt's lymphoma in the Middle East. A study of 34 cases. *Cancer* 1985;56:2539-2543.
31. Salem PA, Habboubi N, Anaissie E, Brihi ER, Issa P, Abbas JS, Khalyl MF. Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma. *Cancer Treat Rep* 1985(Jul-Aug);69(7):891-893.
32. Anaissie E, Geha S, Allam C, Jabbour J, Khalyl M, Salem P. Burkitt's lymphoma in the Middle East. In *Burkitt's Lymphoma: A Human Cancer Model*. Lenoir GM, O'Connor GT, Olweny CLM, Editors. IARC Scientific Publications, Lyon. 1985;60:129-134.
33. Salem PA, El-Hashimi L, Anaissie E, Khalyl M, Allam C. Immuno-proliferative small intestinal disease. Chapter in *Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances*. Cavalli F, Bonadonna G, Rozenzweig M, Editors. MartinusNijhoff Publishing 1985;pp 269-277.
34. Salem P, Khalyl M, Jabboury K, Hashimi L. The 5-day continuous infusion of cis-platinum: An update on toxicity pattern. Chapter in *Clinical Applications of Continuous Infusions, Chemotherapy, and Concomitant Radiation Therapy*. Rosenthal CJ and Rotman M, Editors. Plenum Press, New York 1985;pp 101-105.
35. Salem P, Anaissie E, Allam C, Geha S, Hashimi L, Ibrahim N, Jabbour J, Khalyl M. Non-Hodgkin's lymphomas in the Middle East. A study of 417 patients with emphasis on special features. *Cancer* 1986;58:1162-1166.
36. Salem PA. Non-Hodgkin's lymphomas. Management strategy and future research. *J Med Liban* 1986;36(3): 107-115.
37. Salem P, El-Hashimi L, Anaissie E, Geha S, Habboubi N, Ibrahim N, Khalyl M, Allam C. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. *Cancer* 1987;59:1670-1676.
38. Shikhani A, Samara M, Allam C, Salem PA, Lenhard R. Primary lymphoma in the salivary glands: report of five cases and review of the literature. *Laryngoscope* 1987;97:1438-1442.
39. Salem PA. Mediterranean Abdominal Lymphoma (Immunoproliferative Small Intestine Disease). Chapter 36 in *Manual of Adult and Paediatric Medical Oncology*. Monfardini S, Brunner K, Crowther D, Eckhardt S, Olive D, Tenneberger S, Veronesi A, Whitehouse J, Wittes R, Editors. Springer-Verlag, Inc, New Jersey 1987;pp 375-377.
40. Ibrahim NK, Khouri FP, Salem PA. VP-16-based regimen in adult acute nonlymphoblastic leukemia. *Oncology* 1988;45(1):21-23.
41. Kim EE, Abello R, Wallace S, Coan J, Salem PA. Gated MRI imaging of malignant cardiac tumors. *Mag Resonance Imaging* 1988;6:129.

42. Kim EE, Wallace S, Abello R, Coan JD, Ewer MS, Salem PA, Ali MK. Malignant cardiac fibrous histiocytomas and angiosarcomas: MR features. *J Comput Assist Tomogr* 1989(Jul-Aug);13(4):627-632.
43. Zakhem A, Aftimos G, Kreidy R, Salem P. Malignant strumaovarii: report of two cases and selected review of the literature. *J SurgOncol* 1990;43:61-65.
44. Mavligit GM, Zukiwski AA, Gutterman JU, Salem P, Charnsangavej C, Wallace S. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. *J ClinOncol* 1990;8:319-324.
45. Mavligit GM, Zukiwski AA, Salem PA, Lamki L, Wallace S. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. *Cancer* 1991(Jul 15);68(2):321-323.
46. Karr RA, Best CG, Salem PA, Toth, BB. Synovial sarcoma metastatic to the mandible: report of two cases. *J Oral MaxillofacSurg* 1991(Dec);49(12):1341-1346.
47. Gonzalez R, Salem P, Bunn PA Jr, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. *MolBiother* 1991;3:192-196.
48. Salem PA. Mediterranean abdominal lymphoma. A new pathological classification. *Chemotherapia* 1992(Aug).
49. Salem PA. Evolution of chemotherapy in the treatment of sarcomas. *Chemotherapia* 1992(Aug).
50. Jones D, Levin B, Salem P. Primary Small Intestinal Lymphomas. Chapter 69 in *Gastrointestinal Disease: Pathophysiology/ Diagnosis/ Management*, 5th Edition. Sleisenger MH and Fordham JS, Editors; Scharschmidt BF and Feldman M, Associate Editors. WB Saunders Company 1993:pp 1378-1392.
51. Kim EE, Cho J-S, Salem P, Ro JY, Mountain CF. Case Report: Mediastinal synovial sarcoma. *Cancer Bulletin* 1993;45:370-372.
52. Salem P and Jones, D. Treatment of Malignant Neoplasms of the Mucosa-Associated Lymphoid Tissues (MALT). Chapter 47 in *The Non-Hodgkin's Lymphomas*, 2nd Edition. Ian Magrath, Editor. Arnold 1997:pp 989-1005.
53. Salem PA. Breast Cancer: Advances in Early Detection and Prevention. *Medical Interface* 1996(Aug);9(8).
54. Salem PA. Recapturing compassion in medicine: A book review. In *Medicine: Preserving the Passion in the 21<sup>st</sup> Century*, 2<sup>nd</sup> edition. Texas Medicine 2005(Sep):pp13-14.
55. Salem PA and Estephan FF. Immunoproliferative small intestinal disease: current concepts. *Cancer J* 2005(Sep-Oct);11(5):374-382.
56. Salem PA. Lymphoma: diagnosis and treatment. St. Luke's Cancer Program 2007 Annual Report. 2007(Dec).
57. Salem PA. Michael E. DeBakey, M.D.: the real man behind the genius. *Methodist DeBakey Cardiovasc J* 2010(Jan-Mar);6(1):42-44.
58. Salem PA. Why Don't We Cure More Cancer Patients? (Editorial) *Houston Chronicle* 2013(Apr 28).
59. Mach CM, Kim J, Soibam B, Creighton CJ, Hawkins SM, Zigelboim I, Goodfellow P, Gunaratne PH, Odunsi K, Salem PA, Anderson ML. Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. *Cancer Lett* 2013(Jul 28);335(2):314-322.

#### Presentations and Abstracts

60. Kaufman RJ and Salem PA. Recurrent mammary cancer - endocrine management after "prophylactic castration." 10th Intl Cancer Cong, Abstract #835, 6:517, 1970.
61. Salem PA and Sykes M. Effect of topical 5-fluorouracil on normal skin. 10th Intl Cancer Cong, Abstract #798, 6:493, 1970.

62. Hart J, Ho D, Salem PA, Frei E. Clinical and kinetic evaluation of continuous 5-day Ara-c in melanoma. *AmAssoc Cancer Res, Abstract #401, 13:101, 1972.*
63. Salem PA, Hajj A, Shahid M, Azzam S, Alami S. Experience with exploratory laparotomy in Hodgkin's disease in the Middle East. *11th Intl Cancer Cong, Part 1-2:276, 1974.*
64. Salem PA and Hajj A. Role of the hospital-based cancer registry: The experience of the American University of Beirut Hospital. *6th ScienMtgLebAssoc for Advancement of Science, Beirut, Proceedings of the meeting, p 291, 1974.*
65. Salem PA, Hajj A, Alami S, Nassar V. Mediterranean abdominal lymphoma. *3rd Intl Symp on Detection and Prevention of Cancer, New York, 1976.*
66. Salem PA, Sinno B, Hajj A, Kuzhaya S. High dose intermittent therapy with DTIC in melanoma and other solid tumors. *AmAssoc Cancer Res, Abstract #462, 17:116, 1976.*
67. Salem PA and Nassar VH. Primary small intestine lymphoma with malabsorption – A distinct clinico-pathological entity. *Am SocClinOncol, Abstract #C-138, 17:271, 1976.*
68. Salem PA and Parsi M. Combination chemotherapy in the treatment of inflammatory breast cancer. *AmAssoc Cancer Res, Abstract #82, 18:21, 1977.*
69. Salem PA and Risk G. Hepatic arterial combination chemotherapy in the treatment of primary malignant lymphomas in the liver. (Abstract) *Am SocClinOncol, 18:268, 1977.*
70. Salem PA, Bodey G, Freireich E. Current clinical status of cis-dichlorodiammineplatinum II (DDP) in cancer therapy. *Annual Meeting, Texas Medical Assoc, 1977.*
71. Salem PA and Tarraf F. Lebanon's experience with a hospital based cancer registry. *1st Middle East Cancer Conference, Egypt, 1977.*
72. Salem PA, Nassar V, Hajj A, Salem A, Alami A. The role of staging laparotomy in the total management of primary small intestinal lymphoma. *1st Middle East Cancer Conference, Egypt, 1977.*
73. Hall, Salem PA, Benjamin R, Lu K, Loo TL, Murphy W, Wharton JT, Bodey G. Continuous intravenous infusion (civi) of cis-dichlorodiammine-platinum II (DDP): A clinical toxicologic and pharmacologic study. *Am SocClinOncol, Abstract #C-441, 19:417, 1978.*
74. Salem PA, Parsi M, Tavelian S. Intra-hepatic arterial combination chemotherapy with adriamycin, cyclophosphamide and 5-fluorouracil in the treatment of metastatic liver disease from breast cancer. *AmAssoc Cancer Res, Abstract #45, 19:12, 1978.*
75. Salem PA, Haddad F, Brihi E, Issa P. Treatment of glioblastoma multiforme with CCNU and brain irradiation. *Am SocClinOncol, Abstract #C-56, 19:320, 1978.*
76. Salem PA. Problems related to the study of primary small intestinal lymphomas in the Middle East. (Abstract) *3rd Intl Symp of Oncol, Tehran, 1978.*
77. Salem PA, Nassar V, Hajj A, Alami S, Salem A. Mediterranean abdominal lymphoma – the experience of the American University of Beirut. *12th Intl Cancer Cong, Abstract #W62/6, 12:954, 1978.*
78. Hajj A, Salem PA, Nassar V, Issa P, Brihi E, Salem A. Survival of patients with Mediterranean abdominal lymphoma. *12th Intl Cancer Cong, Abstract #W61/19, 12:949, 1978.*
79. Salem PA, Mouradian S, Badran G. Combination chemotherapy in the treatment of advanced Mediterranean abdominal lymphoma. *Am SocClinOncol, Abstract #C-109, 20:317, 1979.*
80. Salem PA, Jabboury K, Khalyl M. Cis-dichlorodiammineplatinum by 5-day continuous infusion-toxicity pattern. *AmAssoc Cancer Res, Abstract #336, 20:84, 1979.*
81. Salem PA, Jabboury K, Khalyl M. Further studies with cis-dichlorodiammineplatinum as a continuous 5-day infusion. *AmAssoc Cancer Res, Abstract #716, 21:179, 1980.*

82. Salem PA, Nassar V, Alami S, Jabboury K, Khalyl M. Immuno-proliferative small intestinal disease – A potentially preventable disease. 4th Intl Symp on Prevention and Detection of Cancer, 3:448, 1980.
83. Salem PA, Jabboury K, Hashimi L, Khalyl M. Preliminary studies with vindesine. (Abstract) Am SocClinOncol, 22:435, 1981.
84. Salem PA, Khalyl M, Rizk G, Jabboury K, Hashimi L. Intra-hepatic artery infusion chemotherapy with cisplatin in the treatment of metastatic liver from breast cancer. (Abstract) AmAssoc Cancer Res, 22:191, 1981.
85. Salem PA, Nassar V, Allam C, Alami S, Salem A, Jabboury K, Hashimi L, Khalyl M. Immunoproliferative small intestinal disease – A new and distinct form of malignant lymphoma. Intl Conf on Malignant Lymphoma – Current Status and Prospects, Lugano, 1981.
86. Salem PA, Nassar V, Allan C, Salem A, Jabboury K, Hashimi L, Khalyl M. Mediterranean abdominal lymphoma – An update. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
87. Hashimi L, Allam C, Khalyl M, Issa P, Brihi E, Salem PA. Primary gastrointestinal lymphomas – The experience of an academic referral center in the Middle East. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
88. Salem PA, Issa P, Brihi E, Obeid S, Allam C, Tarraf F, Khalyl M. The cancer program at the American University of Beirut Medical Center – A model for the establishment of future cancer programs in the Middle East. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
89. Hannoun J, Habboubi N, Allam C, Khalyl M, Brihi E, Issa P, Salem PA. Large cell lymphoma presenting as primary breast cancer –A report of four cases. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
90. Hashimi L, Anaissie E, Allam C, Khalyl M, Salem PA. Childhood abdominal lymphomas in the Middle East. (Abstract) 2nd Intl Conf on Malignant Lymphoma, Lugano, 1984.
91. Anaissie E, Geha S, Allam C, Jabboury K, Obeid M, Issa P, Brihi E, Khalyl M, Shikhani A, Samara M, Salem PA. Waldeyer's Ring lymphomas – A study of 83 cases from the Middle East. 2nd Intl Conf on Malignant Lymphoma, Lugano, 1984.
92. Salem PA, Hashimi L, Anaissie E, Khalyl M, Allam C. Primary intestinal lymphoma of adults in the Middle East. (Abstract) 4th Mediterranean Conf of Chemo, Rhodes, 1984.
93. Shikhani A, Anaissie E, Allam C, Salem PA, Samara M. Primary lymphoma of the salivary glands – Report of 4 cases and review of the literature. Intl Conf on Head and Neck Cancer, Baltimore, 1984.
94. Salem PA, Habboubi N, Anaissie E, Brihi E, Issa P, Abbas J, Khalyl M. Cis-dichlorodiammineplatinum (II) is effective in the treatment of anal squamous cell carcinoma. (Abstract) Am SocClinOncol, 4:78, 1985.
95. Anaissie E, Geha S, Allam C, Jabboury K, Hashimi L, Khalyl M, Salem PA. Non-Hodgkin's lymphoma in the Middle East. AmAssoc Cancer Res, Abstract #580, 26:147, 1985.
96. Salem PA, Khalyl M, Jabboury K, Hashimi L. The 5-day continuous infusion of cisplatin – An update on toxicity pattern. (Abstract) 14th Intl Conf of Chemo, Kyoto, 1985.
97. Salem PA, Allam C, Hashimi L, Anaissie E, Khalyl M. Immunoproliferative small intestine disease – A disease of the Middle East and Mediterranean countries. (Abstract) 14th Intl Cancer Conf, Budapest, 1986.
98. Anaissie E, Geha S, Allam C, Jabboury K, Hashimi L, Khalyl M, Salem PA. Primary extra-nodal lymphoma in the Middle East. (Abstract) 14th Intl Cancer Conf, Budapest, 1986.
99. Salem PA: Immunoproliferative small intestine disease – The only human lymphoma associated with a tumoral marker. 2 Congresso Internazionale Sui Markers Tumoriali, Napoli, p. 63, 1986.
100. Salem PA, Anaissie E, Geha S, et al. Primary extra nodal lymphoma in the Middle East. (Abstract) 3rd Intl Conf on Malignant Lymphoma, Lugano, 1987.
101. Salem PA. Immunoproliferative small intestinal disease: New concepts in pathology. (Abstract) Am

SocClinOncol, 6:244, 1987.

- 102.Salem PA, Hashimi L, Allam C. Immunoproliferative small intestinal disease – The only human lymphoma associated with a biological marker and a recognizable benign phase. Am SocClinOncol, Abstract #A945, 7:244, 1988.
- 103.Jabboury K, Hortobagyi G, Holmes FA, Frye D, Salem PA. Phase II gallium nitrate infusion in breast cancer. AmAssoc Cancer Res, Abstract #1446, 29:363, 1988.
- 104.Salem PA, Zukiwski A, Bunn P, Robinson W, Lamb R, Benjamin RS, Spitler L, Scannon P, Ackerman S. Treatment of advanced metastatic melanoma using single dose murine monoclonal antibody ricin A chain immunotoxin using dose escalation. Phase I study. (Abstract) 1st Intl Symp on Immunotoxins, p. 55, 1988.
- 105.Salem PA, Zukiwski A, Robinson W, Bunn P, Lamb R, Benjamin RS, Spitler L, Wedel N, Ackerman S. Treatment of advanced metastatic melanoma using single dose murine monoclonal antibody – Ricin A chain immunotoxin using dose escalation. A phase I study. AmAssoc Cancer Res, Abstract #1147, 30:288, 1989.
- 106.Salem PA, Zukiwski A, Benjamin RS, Wallace S, Levitt D, Mavligit G. Arterial infusion of interleukin-2 (IL-2) for treatment of hepatic metastases from GI leiomyosarcoma: Predisposition of hypersensitivity to iodine-containing media. AmSocClinOncol, Abstract #1252, 8:322, 1989.
- 107.Legha S, Papadopoulos N, Plager C, Usakewicz J, Salem PA, Nicaise C, Benjamin R. A comparative evaluation of the uroprotective effect of mercaptoethane sulfonate (MESNA) and N-acetylcysteine (NAC) in sarcoma patients treated with ifosfamide. AmSocClinOnc, Abstract #1205, 9:311, 1990.
- 108.Linke KA, Benjamin RS, Evans HL, Salem PA, and Benjamin RS: Phase I-II study of IL-2 used as a continuous infusion in patients with metastatic melanoma. Am Assoc Cancer Res, Abstract #A1217, 31:176, 1990, and Am SocClinOnc, 9:217, 1990.
- 109.Legha S, Fiana M, Plager C, Papadopoulos N, Salem PA, Benjamin RS. Phase I-II study of IL-2 used as a continuous infusion in patients with metastatic melanoma. AmAssoc Cancer Res, Abstract #1047, 31:176, 1990.
- 110.Salem PA, Steiger S, Benjamin RS. Phase II study of THP-adriamycin (Pirarubicin) and DTIC in advanced soft tissue sarcomas. (Abstract) 3rd Intl Conf on Neo-adjuvant Chemotherapy, France, p 24, February 6-9, 1991.
- 111.Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Payer C, Salem PA, Gutterman JU, Benjamin RS. Abrogating chemotherapy CT-induced myelosuppression by GM-CSF: Optimizing the schedule. AmSocClinOncol, Abstract #1241, 10:349, 1991.
- 112.Salem PA, Steiger S, Benjamin RS. Phase II study of THP-Adriamycin (pirarubicin) and DTIC in advanced soft tissue sarcomas. AmSocClinOncol, Abstract #1249, 10:351, 1991.
- 113.Plager C, Papadopoulos NEJ, Salem PA, Benjamin RS. Adriamycin based chemotherapy for leiomyosarcoma of the stomach and small bowel. AmSocClinOncol, Abstract #1251, 10:352, 1991.
- 114.Patel SR, Legha SS, Salem PA, Plager C, Papadopoulos NEJ, Benjamin RS. Evaluation of Ifosfamide in metastatic leiomyosarcomas of gastrointestinal (GI) origin. AmSocClinOncol, Abstract #1252, 10:352, 1991.
- 115.Salem PA, Benjamin RS, Howard J, Gutterman JU. Phase II trial of recombinant interferon alpha 2-b in the treatment of advanced metastatic and refractory sarcomas. AmAssoc Cancer Res, Abstract #1192, 32:200, 1991.
- 116.Salem PA, El-Hashimi L, Anaissie E, Geha S, Habboubi N, Ibrahim N, Khalyf M, Allam C. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. 8th Mediterranean Congr of Chemo, Athens, J Chemother, May 24-29, 1992.
- 117.Salem PA. Advances in the treatment of soft tissue sarcomas. 8th Mediterranean Congr of Chemo, Athens, J Chemother, May 24-29, 1992.